Development & Clinical Translation of ELU001, a Targeted Ultra- Small Topoisomerase 1 C’Dot Conjugate for the Treatment of Solid Tumors

Time: 10:30 am
day: Day Two


  • ELU001 is an ultra-small, 6 nM exatecan conjugated C’Dot Drug Conjugate (CDC) that is targeted to Folate Receptor Alpha via folic acid moieties on its surface
  • Understanding how Folate Receptor Alpha is an ideal target for CDC therapy due to its over expression on a variety of tumors and its limited expression on healthy tissues
  • Due to their size and neutral properties C’Dot Drug Conjugates (CDCs) localize in and penetrate rapidly into solid tumors including difficult to access tumors in the brain and pancreas